Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
Robert Wesolowski(The Ohio State University Wexner Medical Center), William E. Carson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Prashant Trikha(Cancer Genetics (United States)), Mahmoud Abdel‐Rasoul(The Ohio State University), Lynn Schoenfield(The Ohio State University), Ewa Mrózek(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Erin Macrae(McGill University), Joseph Markowitz(University of South Florida), Michael A. Caligiuri(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Kala Levine(The Ohio State University), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Bhuvaneswari Ramaswamy(The Ohio State University), Raquel E. Reinbolt(The Ohio State University), Megan Duggan(The Ohio State University), Maryam B. Lustberg(Yale Cancer Center), Thomas A. Mace(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), John C. Byrd(The Ohio State University), Andrew Stiff(The Ohio State University)
Cited by 72
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response
|Proceedings of the National Academy of Sciences|2012|1.5k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k